Philip O'Reilly1, Raman Malhotra. 1. Corneoplastic Unit, Queen Victoria Hospital, East Grinstead, West Sussex, UK. mrphiliporeilly@gmail.com
Abstract
PURPOSE: To report on 4 patients who developed delayed hypersensitivity reactions to Restylane(®) SubQ and their management. To our knowledge, no cases of delayed hypersensitivity to Restylane(®) SubQ have been previously reported. METHODS: A retrospective case series of 4 patients who were treated with preperiosteal Restylane(®) SubQ to their cheeks, for facial volume augmentation. All 4 patients were subsequently referred with delayed hypersensitivity reactions over a 4-month period. RESULTS: The hypersensitivity reactions occurred from 1 week to 4 months' post-cheek augmentation using Restylane(®) SubQ. All patients had previously (and some since) been treated with other non-animal stabilized hyaluronic acid (NASHA) products without adverse effect. Hyaluronidase led to fast and effective resolution in all cases, although 2 of the patients required repeat treatment. CONCLUSION: Hyaluronidase was effective at treating the inflammatory reaction and breaking up the retained Restylane(®) SubQ in all patients. Although Restylane(®) SubQ should be avoided in these patients, in our experience this does not preclude them from using other similar NASHA products.
PURPOSE: To report on 4 patients who developed delayed hypersensitivity reactions to Restylane(®) SubQ and their management. To our knowledge, no cases of delayed hypersensitivity to Restylane(®) SubQ have been previously reported. METHODS: A retrospective case series of 4 patients who were treated with preperiosteal Restylane(®) SubQ to their cheeks, for facial volume augmentation. All 4 patients were subsequently referred with delayed hypersensitivity reactions over a 4-month period. RESULTS: The hypersensitivity reactions occurred from 1 week to 4 months' post-cheek augmentation using Restylane(®) SubQ. All patients had previously (and some since) been treated with other non-animal stabilized hyaluronic acid (NASHA) products without adverse effect. Hyaluronidase led to fast and effective resolution in all cases, although 2 of the patients required repeat treatment. CONCLUSION: Hyaluronidase was effective at treating the inflammatory reaction and breaking up the retained Restylane(®) SubQ in all patients. Although Restylane(®) SubQ should be avoided in these patients, in our experience this does not preclude them from using other similar NASHA products.